{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hatashima A"],"funding":["NCATS NIH HHS","Ohio State University"],"pagination":["2521-2532"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9724069"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(20)"],"pubmed_abstract":["<b>Aim:</b> To compare the overall survival (OS) among patients who received first-line modified gemcitabine plus nab-paclitaxel (G/nab-P) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) for metastatic pancreatic cancer. <b>Methods:</b> A single-center, retrospective, real-world study was conducted. <b>Results:</b> The median OS was 9.4 months versus 7.5 months in the mFOLFIRINOX and modified G/Nab-P groups, respectively (p = 0.16). An exploratory subgroup analysis excluding patients who received one infusion and had an Eastern Cooperative Oncology Group performance score of 2 demonstrated similar OS of 11.3 months and 8.9 months, respectively. Median progression-free survival and time-to-treatment failure were not significantly different. Higher rates of adverse events were noted with mFOLFIRINOX. <b>Conclusion:</b> mFOLFIRINOX did not significantly prolong OS compared with modified G/nab-P and was associated with increased toxicities."],"journal":["Future oncology (London, England)"],"pubmed_title":["First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population."],"pmcid":["PMC9724069"],"funding_grant_id":["UL1 TR002733","UL1TR001070","UL1 TR001070"],"pubmed_authors":["McLaughlin EM","Arango MJ","Abushahin L","Reardon J","Williams T","Hatashima A","Freeman T"],"additional_accession":[]},"is_claimable":false,"name":"First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.","description":"<b>Aim:</b> To compare the overall survival (OS) among patients who received first-line modified gemcitabine plus nab-paclitaxel (G/nab-P) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) for metastatic pancreatic cancer. <b>Methods:</b> A single-center, retrospective, real-world study was conducted. <b>Results:</b> The median OS was 9.4 months versus 7.5 months in the mFOLFIRINOX and modified G/Nab-P groups, respectively (p = 0.16). An exploratory subgroup analysis excluding patients who received one infusion and had an Eastern Cooperative Oncology Group performance score of 2 demonstrated similar OS of 11.3 months and 8.9 months, respectively. Median progression-free survival and time-to-treatment failure were not significantly different. Higher rates of adverse events were noted with mFOLFIRINOX. <b>Conclusion:</b> mFOLFIRINOX did not significantly prolong OS compared with modified G/nab-P and was associated with increased toxicities.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2024-11-15T08:01:44.221Z","creation":"2024-11-15T08:01:44.221Z"},"accession":"S-EPMC9724069","cross_references":{"pubmed":["35579260"],"doi":["10.2217/fon-2021-1367"]}}